Table 2 Significance of clinicopathologic parameters and TIL markers for survival
From: Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer
Univariate | p value | Multivariate | p value | |
|---|---|---|---|---|
3-Year survival | HR (95% CI) | |||
OS | ||||
ECE (Yes vs. No) | 46.2% vs. 94.4% | 0.000 | 19.713 (2.594–149.833) | 0.004 |
N classification (N2/N3 vs. N0/N1) | 56.8% vs. 93.4% | 0.001 | 6.473 (1.465–28.609) | 0.014 |
Margin (Close/Positive vs. Negative) | 60.6% vs. 80.8% | 0.054 | ||
Stage (early vs. advanced) | 94.7% vs. 66.4% | 0.009 | ||
CD8/FOXP3 (High vs. Low) | 87.3% vs. 63.8% | 0.006 | 0.115 (0.017–0.791) | 0.028 |
LRFS | ||||
Differentiation (Moderate/Poor vs. Well) | 58.5% vs. 93.3% | 0.017 | 8.679 (1.127–66.871) | 0.038 |
Gender (Male vs. Female) | 70.9% vs. 100% | 0.019 | ||
Margin (Close/Positive vs. Negative) | 66.9% vs. 85.8% | 0.030 | ||
ECE (Yes vs. No) | 66.4% vs. 79.0% | 0.095 | ||
RRFS | ||||
ECE (Yes vs. No) | 57.8% vs. 86.0% | 0.018 | 5.268 (1.503–18.466) | 0.022 |
N classification (N2/N3 vs. N0/N1) | 65.2% vs. 81.7% | 0.098 | 16.335 (1.484–179.799) | 0.024 |
Differentiation (Moderate/Poor vs. Well) | 57.7% vs. 88.2% | 0.059 | ||
CD8 (Low vs. High) | 65.9% vs. 83.2% | 0.069 | ||
FOXP3 (High vs. low) | 49.3% vs. 87.3% | 0.000 | 7.487 (1.786–31.395) | 0.006 |
CD8/FOXP3 (High vs. Low) | 84.1% vs. 61.8% | 0.014 | ||
DMFS | ||||
ECE (Yes vs. No) | 66.8% vs. 94.4% | 0.007 | 3.929 (0.489–31.590) | 0.042 |
N classification (N2/N3 vs. N0/N1) | 70.3% vs. 97.1% | 0.003 | 2.980 (0.370–24.033) | 0.035 |
Stage (early vs. advanced) | 100% vs. 72.0% | 0.005 | ||
CD3/CD4 (High vs. Low) | 70.2% vs. 90.5% | 0.026 | ||
CD4/FOXP3 (High vs. Low) | 93.7% vs. 68.4% | 0.002 | 0.032 (0.003–0.384) | 0.007 |